We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Gentronix Secures R&D Award

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Gentronix has announced that it has been awarded a £287,000 Small Business Research Initiative (SBRI) grant from the UK’s Biotechnology and Biological Sciences Research Council (BBSRC).

The purpose of the two-year grant is to assist small businesses initiate or develop new research programmes, and will provide Gentronix with two scientists, cell culture facilities, and supporting laboratory instrumentation at its Manchester Incubator Core Technology Facility premises.

Greenscreen GC, the company’s commercially available yeast-based assay, is already proving an early screening tool in the drug development process.

In particular the assay’s high specificity is demonstrated by the extremely low incidence of false positives compared to other available tests.

The SBRI grant will enable Gentronix to build on this early success, and research and develop additional assays using alternative cell lines.

The aim is to increase screening sensitivity so that no genetically toxic compounds are missed whilst retaining the high specificity required, ensuring potentially valuable lead compounds are not eliminated from further development.